Bays, Harold E.

Current and investigational antiobesity agents and obesity therapeutic treatment targets

Bays, H. E. (2004) · Obesity Research

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 228

Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia

Ballantyne, C. M., Davidson, M. H., MacDougall, D. E., Bays, H. E., DiCarlo, L. A., Rosenberg, N. L., Margulies, J., & Newton, R. S. (2013) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 175

Canagliflozin: effects in overweight and obese subjects without diabetes mellitus

Bays, H. E., Weinstein, R., Law, G., & Canovatchel, W. (2014) · Obesity

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 166

An assessment by the Statin Intolerance Panel: 2014 update

Guyton, J. R., Bays, H. E., Grundy, S. M., & Jacobson, T. A. (2014) · Journal of clinical lipidology

Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug Reactions

Cited by 165

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)

McKenney, J. M., Jones, P. H., Bays, H. E., Knopp, R. H., Kashyap, M. L., Ruoff, G. E., & McGovern, M. E. (2007) · Atherosclerosis

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 150

Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies

Bays, H. E., Ballantyne, C. M., Braeckman, R. A., Stirtan, W. G., & Soni, P. N. (2013) · American Journal of Cardiovascular Drugs

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 141

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance

Nicholls, S., Lincoff, A. M., Bays, H. E., Cho, L., Grobbee, D. E., Kastelein, J. J., Libby, P., Moriarty, P. M., Plutzky, J., Ray, K. K., et al. (2021) · American Heart Journal

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 136

National lipid association annual summary of clinical lipidology 2016

Bays, H. E., Jones, P. H., Orringer, C. E., Brown, W. V., & Jacobson, T. A. (2016) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 128

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial

Bhatt, D. L., Bays, H. E., Miller, M., Cain, J. E., Wasilewska, K., Andrawis, N. S., Parli, T., Feng, S., Sterling, L., Tseng, L., et al. (2023) · Nature Medicine

Lipid metabolism and disordersFibroblast Growth Factor Research

Cited by 121

Once-monthly maridebart cafraglutide for the treatment of obesity—a phase 2 trial

Jastreboff, A. M., Ryan, D. H., Bays, H. E., Ebeling, P. R., Mackowski, M. G., Philipose, N., Ross, L., Liu, Y., Burns, C. E., Abbasi, S. A., et al. (2025) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 110

Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial

Hollander, P., Bays, H. E., Rosenstock, J., Frustaci, M. E., Fung, A., Vercruysse, F., & Erondu, N. (2017) · Diabetes Care

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 106

Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials

Bays, H. E., Banach, M., Catapano, A. L., Duell, P. B., Gotto, A. M., Laufs, U., Leiter, L. A., Mancini, G. B. J., Ray, K. K., Bloedon, L. T., et al. (2020) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug Reactions

Cited by 103

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Bohula, E. A., Scirica, B. M., Inzucchi, S. E., McGuire, D. K., Keech, A. C., Smith, S. R., Kanevsky, E., Murphy, S. A., Leiter, L. A., Dwyer, J. P., et al. (2018) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 94

Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)

Bays, H. E., Braeckman, R. A., Ballantyne, C. M., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., & Soni, P. N. (2012) · Journal of clinical lipidology

Lipid metabolism and disordersFatty Acid Research and Health

Cited by 94

The 'forgotten' bile acid sequestrants: is now a good time to remember?

Bays, H. E., & Goldberg, R. B. (2007) · American Journal of Therapeutics

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 83

From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus

Bays, H. (2009) · Current Medical Research and Opinion

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 83

Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence

Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 83

Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia

Maki, K. C., Bays, H. E., Dicklin, M. R., Johnson, S. L., & Shabbout, M. (2011) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 81

Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat” through improving fat function with antidiabetes therapies

Bays, H. E. (2012) · The American Journal of Cardiology

Cardiovascular Disease and AdiposityAdipokines, Inflammation, and Metabolic Diseases

Cited by 73

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study

Rosenson, R. S., Daviglus, M. L., Handelsman, Y., Pozzilli, P., Bays, H., Monsalvo, M. L., Elliott-Davey, M., Somaratne, R., & Reaven, P. (2019) · Diabetologia

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 73

Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia

Davidson, M. H., Maki, K. C., Bays, H., Carter, R., & Ballantyne, C. M. (2009) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 71

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study

Brinton, E. A., Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Braeckman, R. A., & Soni, P. N. (2013) · Cardiovascular Diabetology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 70

Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022

Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 68

Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease

Bays, H. (2010) · Expert Review of Cardiovascular Therapy

Pharmacology and Obesity TreatmentAdipokines, Inflammation, and Metabolic Diseases

Cited by 66